Search

Your search keyword '"Nicholas L. Hartog"' showing total 11 results
Start Over Author "Nicholas L. Hartog" Publisher elsevier bv
11 results on '"Nicholas L. Hartog"'

1. Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab

Author

Andrew Walls, Jeremy W. Prokop, Surender Rajasekaran, Nicholas L. Hartog, and Alan T. Davis

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Neutrophils, Immunology, Comorbidity, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Leukocyte Count, chemistry.chemical_compound, Tocilizumab, Risk Factors, Severity of illness, Diabetes Mellitus, Humans, Immunology and Allergy, Medicine, In patient, Letters, Lymphocytes, Neutrophil to lymphocyte ratio, Survival analysis, Aged, SARS-CoV-2, business.industry, COVID-19, Middle Aged, Prognosis, medicine.disease, Survival Analysis, COVID-19 Drug Treatment, chemistry, Hypertension, Female, business, Biomarkers
Published
2021

2. Controlled trials needed to prove efficacy and safety of convalescent plasma therapy in coronavirus disease 2019

Author

Amanda Holsworth, Surender Rajasekaran, and Nicholas L. Hartog

Subjects
Pulmonary and Respiratory Medicine, 2019-20 coronavirus outbreak, Convalescent plasma, Coronavirus disease 2019 (COVID-19), biology, SARS-CoV-2, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Immunization, Passive, COVID-19, Virology, Immunoglobulin G, Plasma, Immunization, Perspective, biology.protein, Humans, Immunology and Allergy, Medicine, business, COVID-19 Serotherapy
Published
2021

3. Institution of clinic scheduling guidelines for early introduction of peanut in high risk infants

Author

Andrew Kampfschulte, Nicholas L. Hartog, and Theodore E. Kelbel

Subjects
Male, Risk, Pulmonary and Respiratory Medicine, Early introduction, Arachis, business.industry, Immunology, Scheduling (production processes), Infant, Allergens, medicine.disease, Appointments and Schedules, Humans, Immunology and Allergy, Medicine, Female, Peanut Hypersensitivity, Medical emergency, business, Referral and Consultation, Skin Tests, High risk infants
Published
2019

4. Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Author

Kari C. Nadeau, Anthony R. Ricci, Rosalba E. Puente, Karin S. Coyne, Acklema Mohammad, Patricia H. Stewart, Peggy Rubio O’Connor, Kevin R. Murphy, Nathan James Lesch, Pulin P. Patel, Russell Settipane, Reneé Stadtler, David C. Mares, Jeffrey Rehm, James M. Eudicone, Rabinder Sidhu, Weily Soong, Christine Czajkowski, Allison Ramsey, Amanda L. Michaud, Lori A. Bowers, Xavier Soler, Theodore E. Kelbel, Andrew M. Smith, S. Shahzad Mustafa, Ewa Rakowski, Martha V. White, Raji M. Ayinla, Robert A. Wise, Bruce M. Schnapf, Maxcie M. Sikora, Brett V. Kettelhut, Sherif Al-Farra, Jason M. Bellak, Tabarak Qureshi, Vipin Jain, Adam T. Cherry, Danuel Hamlin, Jennifer Trevor, Taiwen Chen, Lindsay D. Humes, Joseph Dominic Fisher, Neal Jain, Sonia N. Bains, James E. Pearl, Florence Ida Hsu, Patricia L. Luthin, Ziad R. Mattar, Chitra R. Natalie, Edward Schuman, Kartik Shenoy, Susan Estrella-Eades, Mitchell Smith, Gary N. Gross, Ileen Gilbert, Cara Kraft, Francis J. Averill, William McCann, Bradley E. Chipps, Howard J. Lee, J. Paul Cook, Leslie A. Stefanowicz, B. Steele Rolston, Jonathan R. Romeo, R. Sharon Chinthrajah, Sami Abdul Jawad, Brian Stone, Eugene R. Bleecker, Daisy Arce, David G. Hill, John G. Southard, Justin Greiwe, Jonathan Ilowite, Christine Anderson, Joann Blessing-Moore, Jorge Manuel Mercado, Amy Palmer, James P. Krainson, Jill Hanson, Sarah Villegas, Sandra G. Adams, Ellen R. Sher, Karen L. Gregory, Thomas P. Miller, Hassan Nasir, David Pham, Neil Parikh, Bryan Krajicek, John Gedell, Gale Harding, Devi K. Jhaveri, Steven L. Wise, Salim Surani, Maeve Edel O’Connor, Alan Gaines, Franco Barsanti, Andrew S. Kim, Matthew C. Wilson, Andrew A. White, David A. Beuther, Javier Perez-Fernandez, Igor Barjaktarevic, Melvin Lee Morganroth, Matthew Hegewald, Shyamsunder Subramanian, H. Gandhi, Jodi H. Biller, G. Gilbert Head, Da-Wei Liao, Nicholas L. Hartog, Carly Hopkins, Brian D. Modena, Richard A. Wachs, Rory L. Duplantier, Edward Kerwin, Robert S. Zeiger, Laren D. Tan, Aaron K. Kobernick, Randall Brown, Susan M. Smith, Jon Eric Chancellor, Alan Fein, Peter Schochet, Geoffrey Chupp, Mario F. Perez, Ronald C. Balkissoon, Derek K. Johnson, Nabeel Farooqui, Steven G. Kelsen, Diego J. Maselli, Jessica Freyer Most, Pinkus Goldberg, and Deborah Simmons

Subjects
Adult, Predictive validity, medicine.medical_specialty, Adolescent, Exacerbation, Specialty, Logistic regression, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Surveys and Questionnaires, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Aged, Asthma, Receiver operating characteristic, business.industry, Reproducibility of Results, medicine.disease, ROC Curve, 030228 respiratory system, Asthma Control Questionnaire, Emergency medicine, Risk assessment, business
Abstract

Background Asthma exacerbation risk increases with worsening asthma control. Prevailing numerical control tools evaluate only current symptom impairment despite the importance of also assessing risk based on exacerbation history. An easy-to-use questionnaire addressing impairment and risk domains of control is needed. Objective To validate a composite asthma control tool that includes impairment and risk assessments (Asthma Impairment and Risk Questionnaire [AIRQ]). Methods Four-hundred forty-two patients aged ≥12 years with physician-diagnosed asthma who were followed in specialty practices completed 15 impairment and risk questions with dichotomized yes/no responses. Patients spanned all Global Initiative for Asthma severities and were classified as well-controlled, not well-controlled, or very poorly controlled according to a standard of Asthma Control Test (ACT) score plus prior-year exacerbations. Logistic regression analyses identified questions with the greatest predictive validity to discriminate among patients and determine cut points for these 3 classifications. Results The final AIRQ comprises 10 equally weighted yes/no impairment and risk questions. The final 10-item models yielded receiver operating characteristic curves of 0.94 to identify well-controlled versus not well-/very poorly controlled and 0.93 to identify well-/not well-controlled versus very poorly controlled asthma, as reflected by the ACT plus prior-year exacerbations standard. Cut points of 0-1, 2-4, and 5-10 best represented well-, not well-, and very poorly controlled asthma. Conclusions AIRQ is a rigorously validated composite measure designed to identify adults and adolescents with varying degrees of asthma control. Ongoing investigations will determine test-retest reliability, responsiveness to change, and predictive ability for future exacerbations.

Published
2020

5. Use Of Omalizumab In Cold Urticaria Refractory To Therapy

Author

Patricia Choi and Nicholas L. Hartog

Subjects
medicine.medical_specialty, Refractory, business.industry, Immunology, Immunology and Allergy, Medicine, Omalizumab, Cold urticaria, business, medicine.disease, Dermatology, medicine.drug
Published
2020

8. Neuropsychiatric Associations with Drug Allergy

Author

Keerthi R. Karamched, Nicholas L. Hartog, and H. James Wedner

Subjects
medicine.medical_specialty, business.industry, Immunology, Drug allergy, medicine, Immunology and Allergy, medicine.disease, business, Dermatology
Published
2017

Catalog

Books, media, physical & digital resources
See catalog results